Top 10 sleep disorder stories of 2023
Click Here to Manage Email Alerts
Healio Pulmonology has compiled the top news on sleep disorders posted in 2023.
Readers were most interested in learning more about insomnia in women, a nasal spray treatment that improves upper airway collapsibility in patients with obstructive sleep apnea, the FDA clearance of a daytime-nighttime appliance to treat mild to moderate OSA, how OSA impacts emotional memory and the risks associated with sleep deprivation in women.
Here are Healio’s top 10 most-read stories on sleep disorders from 2023.
Insomnia in women common, increases with age
Established and evolving treatments are available to help women with insomnia, the prevalence, symptoms and outcomes of which may vary and intensify with age, according to a speaker at the CHEST Annual Meeting. Read more.
Nasal spray treatment may help patients with obstructive sleep apnea
A drug administered through a nasal spray may be an alternative treatment option for patients with obstructive sleep apnea by improving upper airway collapsibility, according to a study published in CHEST. Read more.
FDA grants 510(k) clearance to obstructive sleep apnea treatment device
The FDA has granted 510(k) clearance to a daytime-nighttime appliance to treat patients with mild to moderate obstructive sleep apnea, according to a manufacturer-issued press release. Read more.
Emotional memory fades overnight in patients with obstructive sleep apnea
Patients with obstructive sleep apnea showed impaired emotional memory after one night of sleep, according to study results published in Annals of the American Thoracic Society. Read more.
Even mild sleep deprivation can lead to cardiovascular health risks for women
Healthy women who delayed their normal bedtime by 1.5 hours showed endothelial dysfunction, which increases risk for cardiovascular disease, according to a study published in Annals of the American Thoracic Society. Read more.
Oral combination obstructive sleep apnea drug lowers disorder severity over 1 month
A combination of atomoxetine and aroxybutynin (AD109, Apnimed) taken for 4 weeks lessened obstructive sleep apnea severity, according to an abstract presented at the American Thoracic Society International Conference. Read more.
‘High efficacy’ with mandibular advancement device in new moderate to severe OSA
For patients with new moderate to severe obstructive sleep apnea, mandibular advancement device therapy reduced disorder severity, according to an abstract presented at the American Thoracic Society International Conference. Read more.
Obstructive sleep apnea combination drug safe, reduces disorder severity over 1 month
A combination of atomoxetine and oxybutynin taken for 30 days lowered baseline obstructive sleep apnea severity, according to results published in Annals of the American Thoracic Society. Read more.
FDA grants 510(k) clearance to at-home sleep apnea test sensor
The FDA has granted 510(k) clearance to an at-home test device (Sunrise) that can diagnose obstructive sleep apnea and other sleep-related breathing disorders, according to a press release. Read more.
Q&A: Bringing attention to risks, disparities in untreated obstructive sleep apnea
To learn more about OSA, risk factors of the disorder and goals of the American Academy of Sleep Medicine and CDC’s “More than a Snore” campaign, Healio spoke with Raman Malhotra, MD, FAASM, professor of neurology in the sleep medicine section at Washington University School of Medicine and AASM past president. Read more.